HETEROARYL COMPOUNDS AND USE THEREOF Russian patent published in 2020 - IPC C07D239/48 C07D401/12 C07D401/14 C07D403/12 C07D403/14 C07D405/12 C07D405/14 C07D407/12 C07D413/12 C07D413/14 C07D417/14 C07D471/04 A61K31/506 A61K31/538 A61K31/5377 A61K35/00 A61P37/00 A61P35/00 A61P19/02 A61P19/08 A61P25/28 A61P29/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to compounds and pharmaceutically acceptable salts thereof, wherein in formula I-b ring A and B are phenyl; R¹ is a reactive group -L-Y, where R¹ is bonded to a ring A in a position other than an atom adjacent to the atom attached to W¹, L and Y are as specified in the claim, W¹ and W² each represent -NR²-; R² is hydrogen, C_1-6 aliphatic group or -C(O)R; m and p are independently 0–4; R^y is halogen; R^x is independently selected from -R, -OR, -O(CH₂)_qOR, or halogen, where q is 1, 2, 3 or 4; and R^v is independently selected from -R, halogen, -OR, -O(CH₂)_qOR, -CN, -NO₂, -SO₂R, -SO₂N(R)₂, -SOR, -C(O)R, -CO₂R, -C(O)N(R)₂, -NRC(O)R, -NRC(O)N(R)₂, -NRSO₂R or -N(R)₂, where q is 1–4. Invention also relates to compositions for inhibiting at least one kinase selected from BTK, TEC, BMX, ITK, ErbB1, ErbB2, ErbB3, ErbB4 and JAK3 or mutants thereof, methods of inhibiting said kinases and mutants thereof, as well as methods of treating disorders mediated by said kinases.

EFFECT: compounds of formula I-b as inhibitors of activity of at least one kinase selected from BTK, TEC, BMX, ITK, ErbB1, ErbB2, ErbB3, ErbB4 and JAK3 or mutants thereof.

47 cl, 25 dwg, 20 tbl, 286 ex